Bain Capital Life Sciences Investors, LLC bought OLMA
January 8, 2025 · Form 4 insider transaction
Bain Capital Life Sciences Investors, LLC bought 300,000 shares of Olema Pharmaceuticals, Inc. at $5.76 per share, a transaction worth $1.73M. The trade was recorded as open-market purchase and disclosed on an SEC Form 4, filed 5 days after the transaction.
Footnotes
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.44 to $5.92, inclusive. The reporting persons undertake to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.; Represents securities held directly by Bain Capital Life Sciences Opportunities IV, L.P. ("BCLS Opportunities IV").; Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of Bain Capital Life Sciences IV General Partner, LLC ("BCLS Fund IV GP"), which is the general partner of Bain Capital Life Sciences Fund IV, L.P. ("BCLS Fund IV"), which is the sole member of Bain Capital Life Sciences Opportunities IV GP, LLC ("BCLS Opportunities IV GP" and, together with BCLSI, BCLS Fund IV GP, BCLS Fund IV, BCLS Opportunities IV GP and BCLS Opportunities IV, the "Bain Capital Life Sciences Entities"), which is the general partner of BCLS Opportunities IV. As a result, each of BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Opportunities IV GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Opportunities IV. BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Opportunities IV GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.